Medable has launched a new patient-first offering that aids life sciences firms in boosting patient access, enrolment, and retention in oncology trials. 

An end-to-end suite, the offering comprises pre-built and verified decentralised clinical trial (DCT) applications such as Total Consent and Televisit, a wide-ranging eCOA oncology library, and protocol design consultation.

It also provides a single entry point for sites, sponsors, and patients.

To expand access, diversity, and retention in trials, the solution aids patients who are receiving rigorous cancer treatments to take part remotely in the at-home setting, as well as on-site. 

It also keeps patients occupied while streamlining the collection of data for sites and sponsors. 

Prompt notifications and reminders aid in guaranteeing compliance while the real-time reporting functionality of the company boosts patient- and caregiver-friendly ePROs.

This approach makes tracking and offering responses to new toxicity and tolerability signals easy. 

By integrating patient trial data with real-world data to capture key endpoints, tokenisation simplifies data collection after the trial for lifetime follow-up.

Medable Therapeutic Area Solutions vice-president Musaddiq Khan said: “The reinvigorated Cancer Moonshot initiative coupled with the FDA’s emphasis on diversity in clinical research is driving an urgent need to improve access to cancer trials. 

“Our DCT offering is designed around the core needs of oncology trials while enabling optionality to improve access and the patient experience. 

“Meeting patients where they are while offering better insight and data to site and study teams improves the experience for everyone and, subsequently, retention.”

This February, the company launched the Medable Partner Network, merging a varied ecosystem of technology, service, data, site and direct-to-patient partners that collaborate to fast-track DCT deployment.